Lys5

Site Information
___MQAIkCVVVGDG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 573766214

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 1 ) , mass spectrometry ( 2 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:	liver cancer ( 1 ) , hepatocellular carcinoma ( 1 )
Relevant cell line - cell type - tissue:	Hep3B (hepatic) ( 1 ) , HepG2 (hepatic) ( 1 ) , Huh7 (hepatic) ( 1 ) , Jurkat (T lymphocyte) ( 2 ) , SNU-387 (hepatic) ( 1 )

Downstream Regulation
Effects of modification on biological processes:	carcinogenesis, inhibited ( 1 ) , signaling pathway regulation ( 1 )

References
1	Ma X, et al. (2022) The E3 ubiquitin ligase MG53 inhibits hepatocellular carcinoma by targeting RAC1 signaling. Oncogenesis 11, 40 35858925 Curated Info
2	Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31 23266961 Curated Info